Fig 1: SH decreased MMP-9 and increased TIMP-1, TIMP-2 levels in both mouse modelSerum samples and section specimen were used to detect these markers. In the 4T1 mouse model, (A) MMP-2, (B) MMP-9, (C) TIMP-1 and (D) TIMP-2 serum levels were tested using ELISA. (E) IHC staining and (F) quantification of MMP-9, TIMP-1 and TIMP-2 expression in 4T1 tumor specimens. (G) IHC staining and (H) quantification of MMP-9, TIMP-1 and TIMP-2 expression in MDA-MB-231 lung specimens. Data are represented as mean ± S.D. of three independent experiments. *P < 0.05, #P < 0.01, SH treated group compared with the untreated control group.
Fig 2: ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
Supplier Page from CUSABIO Technology LLC for Human Tissue Inhibitor Of Matrix Metalloprotease-1 (TIMP-1) ELISA Kit